Compositions and methods for treating retinal degradation
The present disclosure relates to nucleosides, such as compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to nucleosides, such as compositions, and methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.
1. A compound of the following structure:
2. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
3. A method for treating retinal degeneration, comprising: administering an effective amount of a compound of the following structure:
to a subject in need thereof.
4. A method for inhibiting inflammasome activation by Alu RNA associated with a cell, comprising: administering an inhibitory amount of a compound of the following structure:
to a subject.
5. The method of claim 4 , wherein the inflammasome is selected from an NLRP3 inflammasome, an IL-1 beta inflammasome, and a combination thereof.